Suppr超能文献

联合 A20 和含三联基序蛋白 44 作为日本人群乳腺癌患者的不良预后因素。

Combined A20 and tripartite motif-containing 44 as poor prognostic factors for breast cancer patients of the Japanese population.

机构信息

Department of Systems Aging Science and Medicine, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan.

Department of Comprehensive Pathology, Graduate School of Medical and Dental Sciences, Tokyo, Japan.

出版信息

Pathol Int. 2021 Jan;71(1):60-69. doi: 10.1111/pin.13047. Epub 2020 Nov 7.

Abstract

We previously reported that a strong immunoreactivity of tripartite motif-containing 44 (TRIM44) predicts the poor prognosis of patients with invasive breast cancer, and proposed that TRIM44 activates nuclear factor-κB (NF-κB) signaling as a causative mechanism. In the present study, we examined the clinicopathological roles of A20, which is known to be an NF-κB responsive gene, with TRIM44, in an updated cohort. Tissue samples of invasive breast cancer were obtained from 140 Japanese female breast cancer patients who underwent surgical treatment. Immunoreactivities of A20 and TRIM44 were analyzed using specific antibodies for each protein. A positive A20 immunoreactivity was significantly associated with a shorter disease-free survival (P = 0.043) and was positively correlated with TRIM44 immunoreactivity (P = 0.039). Combined use of the immunoreactivities for two proteins revealed that double-positive status for both A20 and TRIM44 immunoreactivities was associated with a shorter disease-free survival (P = 0.012) and was an independent factor for poor prognosis. These results indicate that a combined A20 and TRIM44 immunoreactivity predicted the prognosis of patients with invasive breast cancer. Moreover, the positive correlation between A20 and TRIM44 immunoreactivities suggested that the activation of NF-κB signaling by TRIM44 could occur in clinical breast cancer tissues.

摘要

我们之前报道过三结构域蛋白 44(TRIM44)的强免疫反应性可预测浸润性乳腺癌患者的不良预后,并提出 TRIM44 作为一种致病机制激活核因子-κB(NF-κB)信号通路。在本研究中,我们在一个更新的队列中,用 TRIM44 检测了已知是 NF-κB 反应基因的 A20 的临床病理作用。从 140 名接受手术治疗的日本女性乳腺癌患者中获得了浸润性乳腺癌的组织样本。使用每种蛋白的特异性抗体分析 A20 和 TRIM44 的免疫反应性。A20 的阳性免疫反应性与无病生存期显著相关(P=0.043),并且与 TRIM44 免疫反应性呈正相关(P=0.039)。两种蛋白免疫反应性的联合使用表明,A20 和 TRIM44 免疫反应性均为双阳性与无病生存期较短相关(P=0.012),是预后不良的独立因素。这些结果表明,A20 和 TRIM44 的联合免疫反应性可预测浸润性乳腺癌患者的预后。此外,A20 和 TRIM44 免疫反应性之间的正相关性表明,TRIM44 可以在临床乳腺癌组织中激活 NF-κB 信号通路。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验